PM
Prosight Management Portfolio holdings
AUM
$410M
This Quarter Return
+4.99%
1 Year Return
-14.96%
3 Year Return
+21.81%
5 Year Return
+1.17%
10 Year Return
–
AUM
$197M
AUM Growth
+$197M
(-9.8%)
Cap. Flow
-$23.6M
Cap. Flow
% of AUM
-11.98%
Top 10 Holdings %
Top 10 Hldgs %
62.37%
Holding
44
New
8
Increased
13
Reduced
17
Closed
5
Top Buys
| 1 |
Kura Oncology
KURA
|
$13.7M |
| 2 |
uniQure
QURE
|
$9.38M |
| 3 |
Q32 Bio
QTTB
|
$7.22M |
| 4 |
Bristol-Myers Squibb
BMY
|
$5.78M |
| 5 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
$5.05M |
Top Sells
| 1 |
Cigna
CI
|
$16.8M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$12.7M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$9.75M |
| 4 |
HNGR
Hanger Inc.
HNGR
|
$8.46M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
$7.63M |
Sector Composition
| 1 | Healthcare | 98.13% |
| 2 | Technology | 0.92% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$21B
| $19.4M | 9.77% | 164,619 +41,119 | +33% | +$4.84M |
|
|
2
Bristol-Myers Squibb
BMY
$96B
| $18.6M | 9.39% | 410,490 +127,490 | +45% | +$5.78M |
|
|
3
Kura Oncology
KURA
$686M
| $17.1M | 8.62% | 867,810 +694,916 | +402% | +$13.7M |
|
|
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.8M | 5.94% | 124,965 -50,735 | -29% | -$4.79M |
|
|
5
Iovance Biotherapeutics
IOVA
$807M
| $9.81M | 4.95% | 400,000 -517,080 | -56% | -$12.7M |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $9.63M | 4.86% | 164,300 -88,200 | -35% | -$5.17M |
|
|
HNGR
7
DELISTED
Hanger Inc.
HNGR
| $9.42M | 4.75% | 491,685 -441,863 | -47% | -$8.46M |
|
8
UroGen Pharma
URGN
$900M
| $9.38M | 4.73% | 260,928 +103,066 | +65% | +$3.7M |
|
|
9
uniQure
QURE
$896M
| $9.38M | 4.73% | +120,000 | New | +$9.38M |
|
|
ALBO
10
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $8.17M | 4.12% | 253,327 -16,509 | -6% | -$532K |
|
|
SBBP
11
DELISTED
Strongbridge Biopharma plc.
SBBP
| $7.97M | 4.02% | 2,546,997 +1,613,121 | +173% | +$5.05M |
|
|
12
Q32 Bio
QTTB
$20.9M
| $7.22M | 3.64% | +369,048 | New | +$7.22M |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.69M | 3.37% | 450,000 +200,611 | +80% | +$2.98M |
|
14
Centene
CNC
$14.3B
| $6.63M | 3.34% | 126,500 +48,100 | +61% | +$2.52M |
|
|
15
Cigna
CI
$80.3B
| $4.92M | 2.48% | 31,227 -106,773 | -77% | -$16.8M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.39M | 2.21% | 51,200 -6,184 | -11% | -$530K |
|
17
Aldeyra Therapeutics
ALDX
$351M
| $4.19M | 2.11% | 697,921 +114,621 | +20% | +$688K |
|
18
Gyre Therapeutics
GYRE
$703M
| $4.03M | 2.03% | 547,092 +62,892 | +13% | +$464K |
|
19
Indaptus Therapeutics
INDP
$7.19M
| $3.54M | 1.79% | 815,789 +272,870 | +50% | +$1.18M |
|
20
AC Immune
ACIU
$205M
| $3.13M | 1.58% | 563,900 -146,641 | -21% | -$814K |
|
21
Assembly Biosciences
ASMB
$190M
| $2.7M | 1.36% | 200,000 -114,410 | -36% | -$1.54M |
|
|
TLGT
22
DELISTED
Teligent, Inc
TLGT
| $1.87M | 0.94% | 2,967,721 -73,847 | -2% | -$46.5K |
|
|
WCG
23
DELISTED
Wellcare Health Plans, Inc.
WCG
| $1.85M | 0.93% | 6,500 -34,200 | -84% | -$9.75M |
|
24
ASGN Inc
ASGN
$2.38B
| $1.82M | 0.92% | 30,000 -79,116 | -73% | -$4.79M |
|
|
MTEM
25
DELISTED
Molecular Templates, Inc.
MTEM
| $1.65M | 0.83% | 197,681 -100,109 | -34% | -$836K |
|